R
Raimund Margreiter
Researcher at Innsbruck Medical University
Publications - 184
Citations - 8530
Raimund Margreiter is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Transplantation & Cancer. The author has an hindex of 43, co-authored 184 publications receiving 7756 citations. Previous affiliations of Raimund Margreiter include University of Vienna & University of Innsbruck.
Papers
More filters
Journal ArticleDOI
Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells
Andrey V. Kuznetsov,Vladimir Veksler,Vladimir Veksler,Frank N. Gellerich,Valdur Saks,Raimund Margreiter,Wolfram S. Kunz,Wolfram S. Kunz +7 more
TL;DR: A specially designed substrate/inhibitor titration approach allows the step-by-step analysis of several mitochondrial complexes and allows the detailed characterization of functional mitochondria in their normal intracellular position and assembly, preserving essential interactions with other organelles.
Journal ArticleDOI
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Gerald Brandacher,Alexander Perathoner,Ruth Ladurner,Ruth Ladurner,Stefan Schneeberger,Peter Obrist,Christiana Winkler,Ernst R. Werner,Gabriele Werner-Felmayer,Helmut Weiss,Georg Göbel,Raimund Margreiter,Alfred Königsrainer,Alfred Königsrainer,Dietmar Fuchs,Albert Amberger +15 more
TL;DR: IDO-high expression by colorectal tumor cells enables certain cancer subsets to initially avoid immune attack and defeat the invasion of T cells via local tryptophan depletion and the production of proapoptotic tryPTophan catabolites.
Journal ArticleDOI
The international registry on hand and composite tissue transplantation
Palmina Petruzzo,Marco Lanzetta,Jean-Michel Dubernard,Luis Landin,P. Cavadas,Raimund Margreiter,S. Schneeberger,Warren W. Breidenbach,Christina C. Kaufman,Jerzy Jablecki,Frederic Schuind,Christian C. Dumontier +11 more
TL;DR: Hand transplantation is feasible with a high success rate and satisfactory functional outcome, and patients developed protective sensibility, 90% of them developed tactile sensibility and 72% also a discriminative sensibility.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Methylation changes in faecal DNA: a marker for colorectal cancer screening?
Hannes M. Müller,Michael Oberwalder,Heidi Fiegl,Maria Morandell,Georg Goebel,Matthias Zitt,Markus Mühlthaler,Dietmar Öfner,Raimund Margreiter,Martin Widschwendter +9 more
TL;DR: An assessment of faecal DNA from patients with colorectal cancer and controls to determine the feasibility, sensitivity, and specificity of the SFRP2 methylation approach and identified it as a sensitive single DNA-based marker for identification of coloreCTal cancer in stool samples.